Comparative Pharmacology
Head-to-head clinical analysis: E MYCIN versus ERYPAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E MYCIN versus ERYPAR.
E-MYCIN vs ERYPAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation of peptidyl-tRNA. It may also act as a motilin receptor agonist, enhancing gastrointestinal motility.
Erypoietin receptor agonist; stimulates erythropoiesis by binding to erythropoietin receptors on erythroid progenitor cells.
250-500 mg orally every 6 hours or 500 mg every 12 hours; maximum 4 g/day.
Intravenous: 100 mg every 12 hours for 7 to 14 days.
None Documented
None Documented
1.5-2 hours in adults with normal renal function; prolonged to 4-6 hours in severe hepatic impairment; no significant change in renal impairment due to minimal renal clearance.
Terminal elimination half-life is approximately 3-5 hours in adults with normal renal function; may be prolonged to >10 hours in severe renal impairment
Primarily hepatic metabolism and biliary excretion with significant enterohepatic circulation; approximately 2-15% excreted unchanged in urine; 10-40% excreted in feces via bile; less than 1% eliminated as unchanged drug in feces from unabsorbed drug.
Primarily renal excretion of unchanged drug (~75%) and metabolites; biliary/fecal elimination accounts for ~20%
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic